enGene Therapeutics Inc. Debt Conversion, Converted Instrument, Amount
enGene Therapeutics Inc. (ENGN) reported Debt Conversion, Converted Instrument, Amount of $8.00 million for the 12-month period ending 2023-10-31, per its 10-K filed 2024-12-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2024-12-19
- enGene Therapeutics Inc. debt conversion, converted instrument, amount for fiscal 2023 was $8.00M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2023-10-31 | $8.00M 10-K · filed 2024-12-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |